Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
Oct 18, 2010
DUBLIN and MYSTIC, Conn., Oct 18, 2010 /PRNewswire via COMTEX News Network/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that Dr. Declan Doogan, Chief Medical Officer, is scheduled to present on Amarin's behalf at the NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 2:00 pm. This conference will be held at th...
Sep 16, 2010
DUBLIN and MYSTIC, Conn., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present on Amarin's behalf at the Global UBS Life Sciences Conference on Wednesday, September 22, 2010 at 12:30 pm. This conference will be held at the Grand ...
Aug 17, 2010
Dublin, Ireland and Mystic, Connecticut, USA, August 17, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Colin W. Stewart has been appointed President, Chief Executive Officer (CEO) and a member of the Company’s Board ...
Aug 10, 2010
Dublin, Ireland and Mystic, CT, USA, August 10, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of thi...
Aug 10, 2010
Dublin, Ireland and Mystic, CT, USA, August 10, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reports a financial update as of June 30, 2010. In addition, the Company provides a progress update of its MARINE and ANCHOR trials, the two on-going Phase 3 ...
Aug 3, 2010
Dublin, Ireland and Mystic, CT, USA, August 3, 2010 – Amarin Corporation plc (NASDAQ: AMRN) has scheduled a conference call for Tuesday, August 10, 2010 at 4:00 pm UTC/GMT + 1 hour (11:00 am Eastern Time) to discuss selected financial results and provided a progress update of the Company’s MARINE and ANCHOR, the two Phase 3 cl...
Jul 29, 2010
Dublin, Ireland and Mystic, CT, USA , July 29, 2010 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the 30th Annual Canaccord Genuity Global Growth Conference on Thursday, August 12, 2010 at 1:30pm (EDT). This conference will be held at the I...
Jun 4, 2010
DUBLIN and MYSTIC, Conn., June 4 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq:AMRN - News) today announced that members of its senior management team will be presenting at two upcoming investor conferences. Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sci...
May 13, 2010
Dublin, Ireland and Mystic, CT, USA, May 13, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus o...
May 12, 2010
DUBLIN and MYSTIC, Conn., May 12 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq:AMRN - ...
Apr 27, 2010
Dublin, Ireland and Mystic, CT, USA , April 27, 2010 – Amarin Corporation plc (NASDAQ: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present at Deutsche Bank Securities 35th Annual Health Care Conference.  The presentation will be made on Monday, Ma...
Mar 3, 2010
DUBLIN and MYSTIC, Conn., March 3 /PRNe...
Feb 11, 2010
DUBLIN and MYSTIC, Conn., Feb. 11 -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, is pleased to announce the appointment of Mr. Jan...
Feb 2, 2010
DUBLIN and MYSTIC, Conn., Feb. 2 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announce...
Jan 28, 2010
Dublin, Ireland and Mystic, CT, USA, January 28, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Dr. Declan Doogan, Amarin’s Interim...
= add release to Briefcase